Jivi approved by Health Canada
October 24, 2018 – Please CLICK HERE to read Bayer’s press release announcing the approval of Jivi, a new pegylated recombinant, B-domain deleted, extended half-life factor VIII concentrate.
Hemlibra (emicizumab) approved by Health Canada
August 7, 2018 – Please CLICK HERE to read Roche’s press release announcing the approval of Hemlibra, a new therapy for patients with hemophilia A and inhibitors.
Zonovate now available in Quebec
April 11, 2018 – Please CLICK HERE to read Novo Nordisk’s press release announcing the launch of Zonovate, a treatment for patients with hemophilia A, in Quebec.
Rebinyn enters the Canadian market
April 11, 2018 – Please CLICK HERE to read Novo Nordisk’s press release announcing the launch of Rebinyn, a new long-acting treatment for patients with hemophilia B in Canada.
Deaths of patients receiving emicizumab judged unrelated to drug
On March 29, 2018, following considerable social media activity, Roche released a statement on the deaths of five patients who had been receiving emicizumab.All of the deaths were judged to be unrelated to the use of the drug by the treating physicians. Roche reported that they have strict safety reporting procedures for patients using emicizumab on clinical trials and compassionate use. Based on these assessments and the available information, the current benefit/risk ratio of emicizumab remains unchanged.
Introduction of new rFVIII products by Héma-Québec
February 1, 2018 – That’s right! There will be more changes in the availability of coagulation products in the coming weeks now that Héma-Québec has announced it has awarded new contracts for recombinant factor VIII concentrates. This is the outcome of the call for tenders that took place in the latter half of 2017.